Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency

Törnblom, Hans

doi:10.1111/apt.17300

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We very much appreciate the commentary by Professor Törnblom on our article. 1,2 In particular, we are in agreement with his exhortation to improve treatment options for cannabis use disorders, which are particularly limited.…”

Section: N V I T E D E D I T O R I a L Editorial: Cannabis Use Disord...supporting

confidence: 75%

Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency—authors' reply

Andrews

Sharkey

2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: N V I T E D E D I T O R I a L Editorial: Cannabis Use Disord...supporting

confidence: 75%

Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency—authors' reply

Andrews

Sharkey

2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Amongst DGBI that were more prevalent in the UK than in the other 25 countries pooled, opioid‐induced constipation, chronic nausea and vomiting, and cannabinoid hyperemesis syndrome add further evidence for the role of lifestyle and prescribing practices in influencing DGBI prevalence and variability. Gastrointestinal symptoms such as chronic nausea and vomiting are increasingly recognized as features of cannabis use disorder, 24 and the higher prevalence of cannabinoid hyperemesis in the UK compared with the other 25 countries pooled suggests that there is a need to raise awareness of this amongst acute care physicians in the UK. Recent data from North America suggest that patients with cannabinoid hyperemesis syndrome almost universally have a cannabis use disorder accounting for an increasing burden of emergency department attendances with symptoms related to problematic chronic cannabis use 25 .…”

Section: Discussionmentioning

confidence: 99%

The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study

Jaafari

Houghton

West

et al. 2023

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background: There are minimal epidemiological data comparing the burden of disorders of gut brain interaction (DGBI) in the UK with other countries. We compared the prevalence of DGBI in the UK with other countries that participated in the Rome Foundation Global Epidemiology Study (RFGES) online. Methods:Participants from 26 countries completed the RFGES survey online including the Rome IV diagnostic questionnaire and an in-depth supplemental questionnaire with questions about dietary habits. UK sociodemographic and prevalence data were compared with the other 25 countries pooled together.The Rome Foundation Global Epidemiological Study (RFGES) spanning six continents provided the most comprehensive worldwide data on the prevalence of all 22 Rome IV disorders of gut-brain interaction (DGBI). 1 The global prevalence of these disorders was found to be high, with 40.3% of participants meeting criteria for at least one DGBI. 1 Aside from the overall global prevalence of DGBI and their interactions and overlap, the original study has, importantly, captured data on the burden and impact of these conditions with data on healthcare utilization and impact on quality-of-life worldwide. These data have not only been important in raising awareness of just how prevalent DGBI are on a worldwide scale but have also provided unique opportunities to understand how the prevalence of DGBI may vary amongst countries, and examining sociodemographic factors that may contribute to epidemiological differences, including dietary practices. The first country-level analysis of the RFGES dataset provided detailed national prevalence data for all 22 DGBIs in Israel, and compared the prevalence, healthcare utilization, and quality-of-life data with the other 25 countries that completed the questionnaire using the same Internet-based methodology. 2 However, to our knowledge, no studies have previously compared the epidemiology of DGBI in the UK with their epidemiology worldwide.In the UK, despite DGBI accounting for a significant proportion of gastroenterology outpatient workload, 3 and substantial direct financial costs estimated to be between £1.3 and £2 billion for irritable bowel syndrome (IBS) alone, 4 these chronic disorders are given low priority in the gastroenterology training curriculum, 5-7 are of limited priority for research funding, 8 and there are only a few specialized centers nationally that offer integrated multidisciplinary care for DGBI, despite this being recognized increasingly as the standard of care. 9 Recently updated evidence-based national DGBI guidelines from the British Society of Gastroenterology on IBS and functional dyspepsia (FD) have emphasized the role of making positive diagnoses, and use of sequential first-, second-, and third-line therapies,

show abstract

Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency

Abstract: LINKED CONTENTThis article is linked to Andrews et al papers. To view these articles, visit https://doi.org/10.1111/apt.17265 and https://doi.org/10.1111/apt.17316

Cited by 2 publications

References 4 publications

Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency—authors' reply

Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency—authors' reply

The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study

Contact Info

Product

Resources

About